Verafeye is a catheter-based sensor combined with advanced imaging and machine learning. The system provides live, 360°, high-resolution imagery of the beating heart, as well as real-time tissue analysis to determine where tissue has been fully ablated during catheter ablation procedures.
To prepare for commercialization, the company plans to complete product development, conduct clinical trials, and gain clearance from the U.S. Food and Drug Administration. The goal is to enable physicians to optimize outcomes and safety during catheter ablation in order to improve their success rate and reduce overall costs, the company said.
The financing round was led by Imec.xpand, with participation from the European Innovation Council Fund and existing investors, including LSP and Atlantic Bridge Ventures.
Copyright © 2021 AuntMinnie.com